The FIT Test: The Colon Cancer Screen You Do at Home

What is a FIT test?

A FIT is a fecal immunochemical test. It is a screening test for colorectal cancer that you do at home: you collect a trace of stool from a single bowel movement onto a probe or card, seal it in the tube the kit supplies, and mail it to a lab. The lab tests that sample for human hemoglobin — the oxygen-carrying protein inside red blood cells. That is the entire test.

Fecal immunochemical test (FIT) — a stool test that uses an antibody to detect human hemoglobin specifically.

The word doing the work is immunochemical. The test uses an antibody raised against human globin, so it asks a narrow question: is there human blood in this stool? That narrowness is the improvement over the guaiac card it replaced. The older test ran a chemical reaction that could be set off by things other than human blood, which is why those kits arrived with a list of foods to avoid first. The guaiac FOBT vs immunochemical FIT difference is exactly this: one reacts to a chemical property, the other to a human protein.

It is worth being plain about what a FIT is not, because three other things share its shelf.

• It is not a colonoscopy. It does not look at your colon. Nobody sees anything.
• It is not the colon cancer blood test. That newer category tests a blood draw rather than stool, and answers a different set of questions.
• It is not Cologuard. The FIT test vs Cologuard comparison turns on sensitivity, specificity, price, and how often each gets repeated, and it deserves its own page rather than a paragraph here.

An at-home FIT test also asks less of you than any of them. No bowel prep, no sedation, no ride home, no day off work. The whole of your involvement is one sample and a mailer. That asymmetry — a test that costs you almost nothing, against tests that cost you a day — is why FIT exists as an option at all. It is also why its limits deserve a full hearing rather than a footnote.

Who is the FIT test for?

FIT is for adults at average risk of colorectal cancer who do not have symptoms. The U.S. Preventive Services Task Force recommends screening average-risk adults starting at age 45: a grade B recommendation from 45 through 49, a grade A from 50 through 75, and a grade C — meaning selective, decided case by case — from 76 through 85 1Ref 1U.S. Preventive Services Task Force (USPSTF) (2021).Colorectal Cancer: Screening (Final Recommendation).That recommended average-risk colorectal cancer screening begins at age 45, with a grade B recommendation for ages 45-49, grade A for 50-75, and grade C (selective) for 76-85.. The U.S. Multi-Society Task Force on Colorectal Cancer names FIT as one of the tests that does this job 2Ref 2Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking that places colonoscopy every 10 years and annual FIT in the first tier of screening options, with multitarget stool DNA testing and CT colonography in the second tier..

Two phrases there carry the weight, and both are easy to read straight past.

Average risk. The recommendation is written for people whose history does not already place them in a higher-risk group. A personal history of colorectal cancer or of polyps, inflammatory bowel disease, a strong family history, a known inherited syndrome — these are the kinds of history that take a person outside it. Those situations get a schedule a clinician sets individually, and no page can set it for you.

Without symptoms. Screening means testing people who have no particular reason to think anything is wrong. It is a different activity from investigating a symptom, even when it borrows the same equipment. Someone with rectal bleeding is not a candidate for screening; they are a candidate for a diagnosis. That distinction returns below, and it is the most important thing on this page.

Starting at 45 rather than 50 is a recent change, and not an arbitrary one — but the argument behind it belongs to its own article. What matters here is narrower: if you are 45 or older, average risk, and symptom-free, the FIT is on the menu the guideline hands you.

How accurate is a single FIT test?

Moderately sensitive, highly specific. A systematic review and meta-analysis of fecal immunochemical tests found a pooled sensitivity of about 0.79 and a pooled specificity of about 0.94 for colorectal cancer 3Ref 3Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014).Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.The pooled sensitivity of about 0.79 and pooled specificity of about 0.94 of FIT for colorectal cancer, and the single-round miss rate and false-positive rate that follow from those figures.. Translated: of 100 people who have colorectal cancer at the moment they test, one FIT flags about 79 of them. Of 100 people who do not have it, about 94 are correctly cleared.

Read the other half of each row, because that is where the honesty lives. A sensitivity of 0.79 means one FIT misses about 21 of every 100 cancers present at the moment of testing. A specificity of 0.94 means about 6 of every 100 people without cancer are flagged anyway, and go on to a colonoscopy that finds nothing malignant.

A single FIT flags about 79 of every 100 colorectal cancers and misses about 21 3Ref 3Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014).Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.The pooled sensitivity of about 0.79 and pooled specificity of about 0.94 of FIT for colorectal cancer, and the single-round miss rate and false-positive rate that follow from those figures..

Both numbers describe cancer detection, and only cancer detection. They do not describe how well a FIT finds precancerous polyps, which is a different and harder question that this meta-analysis was not built to answer. Any account of the FIT that quotes 79% without saying what it is 79% of is quoting the number and dropping the fact.

So: is 79 a good number? It is an oddly shaped question, because a screening test's worth is not settled by one round standing alone. The guideline never asked you to trust one round.

Why the guideline says annual, not once

The U.S. Multi-Society Task Force on Colorectal Cancer sorts the screening options into tiers. Two sit in the first tier: colonoscopy every ten years, and FIT every year. Multitarget stool DNA testing and CT colonography sit in the second 2Ref 2Rex DK, Boland CR, Dominitz JA, et al. (U.S. Multi-Society Task Force on Colorectal Cancer) (2017).Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.The tiered ranking that places colonoscopy every 10 years and annual FIT in the first tier of screening options, with multitarget stool DNA testing and CT colonography in the second tier.. Read that first-tier entry closely, because it does not say FIT. It says FIT every year, and those are not the same recommendation.

This is the trade the FIT makes, stated plainly. A colonoscopy asks a great deal of you once a decade. A FIT asks almost nothing of you, twelve months at a time, indefinitely. The interval is the price of the convenience. It is not a detail bolted onto the recommendation; it is the recommendation.

The first-tier option is not "a FIT." It is "a FIT every year."

Which means the failure mode of FIT screening is rarely a laboratory failure. It is a calendar failure. A FIT done once at 45 and never again is not the strategy the task force placed alongside colonoscopy; it is a weaker thing that happens to use the same kit. What the first tier is really buying is program adherence over years — the same envelope arriving, the same sample going back, the result filed and then repeated. A test that is easy enough to actually repeat has a real advantage over a test that looks better on paper and gets skipped.

None of which makes a year a magic number rather than a chosen one. Why twelve months and not twenty-four, and what evidence sits under that interval, is a question with its own answer and its own page.

What does a positive FIT mean?

A positive FIT means the lab found human hemoglobin in your sample. It does not mean cancer, and it is not a diagnosis. It means something in the gastrointestinal tract put blood into the stool on the day you collected it — and the only way to learn what is a colonoscopy. That is the entire obligation a positive result creates.

Blood in stool has many possible sources, and the FIT does not distinguish between any of them. It cannot tell a polyp from a hemorrhoid, or either from something else. It reports a protein, not a place. Which is precisely why a positive routes to an examination that can see, rather than to an explanation that merely sounds reasonable.

What the colonoscopy is often looking for is a polyp. Colon polyps are growths on the lining of the colon or rectum. Most are benign, but some can become cancerous over time, and that is the whole rationale for taking them out when they are found 4Ref 4National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2017).Definition & Facts for Colon Polyps.The definition of colon polyps as growths on the colon or rectal lining that are usually benign but can become cancerous over time, and the rationale for removing them.. A colonoscopy after a positive FIT is therefore not only a look. It is potentially the removal of the thing that would have become the problem.

A positive FIT is not a diagnosis. It is an appointment.

And the appointment is covered. A follow-up colonoscopy performed after a positive stool test is covered as screening rather than billed as a fresh diagnostic procedure 5Ref 5American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That the ACA requires private insurers and Medicare to cover USPSTF-recommended colorectal screening with no patient cost-sharing, that polyp removal during a screening colonoscopy is included, that a follow-up colonoscopy after a positive stool test is covered as screening, and that Medicaid coverage varies by state.. That is worth knowing before the positive result arrives, because cost fear is a real reason people stall on the follow-up — and stalling is the one response that turns a working test into a useless one.

What a negative FIT does not mean

A negative FIT means no human hemoglobin was detected in that sample, on that day. It does not mean your colon is clear, and it is not a clean bill of health. One FIT misses about 21 of every 100 colorectal cancers present at the time of testing 3Ref 3Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014).Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis.The pooled sensitivity of about 0.79 and pooled specificity of about 0.94 of FIT for colorectal cancer, and the single-round miss rate and false-positive rate that follow from those figures.. That miss rate is the reason the result comes with a date attached and a plan to repeat it.

There is a sharper version of this, and it is why the section exists.

A FIT is a test for people without symptoms. If you have a symptom, a negative FIT has answered a question you did not ask, and it is not evidence about the question you did. Screening tests are calibrated for people with no reason to suspect anything. Put one in front of a symptom and it becomes a source of false comfort, which is worse than no test at all.

The symptoms that make screening the wrong tool are not subtle ones:

• Visible blood in the stool, or bleeding from the rectum.
• A change in bowel habit that has persisted for weeks — new looseness, new constipation, stools that have narrowed.
• Iron-deficiency anemia turning up on a blood test with no obvious cause.
• Weight loss you did not intend. Unintentional weight loss is a red flag that warrants a workup for serious disease, and gastrointestinal malignancy is among the causes that workup goes looking for 6Ref 6Gaddey HL, Holder KK (2021).Unintentional Weight Loss in Older Adults.That unintentional weight loss is a red flag warranting a workup for serious disease, with malignancy including gastrointestinal cancers among the leading causes..

A negative FIT does not touch any of those. A negative FIT alongside any of those is not a reason to wait. The move is a clinician's appointment now, not a rescreen next year. This is the one place the convenience of the test turns into a hazard: a normal result arriving in the mail is a very easy thing to be relieved by.

FIT answers a question about people with no symptoms. A symptom is a different conversation, on a different timeline.

What does a FIT test cost?

For most insured adults in the recommended age range, a FIT costs nothing at the point of care. The Affordable Care Act requires private insurers and Medicare to cover the colorectal cancer screening the USPSTF recommends with no patient cost-sharing — no copay, no coinsurance, nothing applied to a deductible 5Ref 5American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That the ACA requires private insurers and Medicare to cover USPSTF-recommended colorectal screening with no patient cost-sharing, that polyp removal during a screening colonoscopy is included, that a follow-up colonoscopy after a positive stool test is covered as screening, and that Medicaid coverage varies by state.. FIT is one of those recommended tests. Medicaid coverage varies from state to state 5Ref 5American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That the ACA requires private insurers and Medicare to cover USPSTF-recommended colorectal screening with no patient cost-sharing, that polyp removal during a screening colonoscopy is included, that a follow-up colonoscopy after a positive stool test is covered as screening, and that Medicaid coverage varies by state..

That coverage reaches further than most people expect, and the extensions are the ones that matter:

• Polyp removal during a screening colonoscopy is included rather than billed as a separate procedure 5Ref 5American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That the ACA requires private insurers and Medicare to cover USPSTF-recommended colorectal screening with no patient cost-sharing, that polyp removal during a screening colonoscopy is included, that a follow-up colonoscopy after a positive stool test is covered as screening, and that Medicaid coverage varies by state..
• A colonoscopy done because a stool test came back positive is covered as screening 5Ref 5American Cancer Society (2024).Insurance Coverage for Colorectal Cancer Screening.That the ACA requires private insurers and Medicare to cover USPSTF-recommended colorectal screening with no patient cost-sharing, that polyp removal during a screening colonoscopy is included, that a follow-up colonoscopy after a positive stool test is covered as screening, and that Medicaid coverage varies by state..

The second point is the one worth carrying around. The most common suspicion about a free FIT is that it is a loss leader — a no-cost test whose real job is to hand you an expensive one. On the coverage rules as they stand, the follow-up after a positive stool test is screening, not a new diagnostic event.

The rules do have edges, and the edges are where surprise bills come from: plans differ, some older plans sit outside the requirement, and how a procedure is coded on the day can change what lands in the mail eight weeks later. Those mechanics have their own article and earn it. What belongs here is narrower and worth saying flatly: nothing about the FIT itself, or about the colonoscopy a positive FIT earns you, is designed to cost you money.